|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DCC |
Gene summary for DCC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DCC | Gene ID | 1630 |
| Gene name | DCC netrin 1 receptor | |
| Gene Alias | CRC18 | |
| Cytomap | 18q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P43146 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1630 | DCC | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.29e-02 | 2.02e-01 | -0.059 |
| 1630 | DCC | HTA11_7469_2000001011 | Human | Colorectum | AD | 5.31e-07 | 7.95e-01 | -0.0124 |
| 1630 | DCC | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.07e-08 | 6.14e-01 | 0.2585 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:012003213 | Lung | AIS | regulation of plasma membrane bounded cell projection assembly | 37/1849 | 186/18723 | 2.67e-05 | 8.60e-04 | 37 |
| GO:006049113 | Lung | AIS | regulation of cell projection assembly | 37/1849 | 188/18723 | 3.41e-05 | 1.05e-03 | 37 |
| GO:190211511 | Lung | AIS | regulation of organelle assembly | 34/1849 | 186/18723 | 3.06e-04 | 5.62e-03 | 34 |
| GO:003514811 | Lung | AIS | tube formation | 27/1849 | 148/18723 | 1.25e-03 | 1.58e-02 | 27 |
| GO:000716323 | Lung | AAH | establishment or maintenance of cell polarity | 24/613 | 218/18723 | 2.21e-07 | 1.01e-04 | 24 |
| GO:003001023 | Lung | AAH | establishment of cell polarity | 17/613 | 143/18723 | 4.53e-06 | 1.22e-03 | 17 |
| GO:003001031 | Lung | MIAC | establishment of cell polarity | 27/967 | 143/18723 | 4.16e-09 | 4.27e-06 | 27 |
| GO:000716332 | Lung | MIAC | establishment or maintenance of cell polarity | 34/967 | 218/18723 | 7.70e-09 | 4.94e-06 | 34 |
| GO:00602711 | Lung | MIAC | cilium assembly | 37/967 | 337/18723 | 1.29e-05 | 9.85e-04 | 37 |
| GO:00447821 | Lung | MIAC | cilium organization | 38/967 | 368/18723 | 3.93e-05 | 2.08e-03 | 38 |
| GO:012003221 | Lung | MIAC | regulation of plasma membrane bounded cell projection assembly | 19/967 | 186/18723 | 3.58e-03 | 4.56e-02 | 19 |
| GO:006049121 | Lung | MIAC | regulation of cell projection assembly | 19/967 | 188/18723 | 4.03e-03 | 4.84e-02 | 19 |
| GO:000716318 | Oral cavity | OSCC | establishment or maintenance of cell polarity | 129/7305 | 218/18723 | 1.16e-09 | 2.86e-08 | 129 |
| GO:19021155 | Oral cavity | OSCC | regulation of organelle assembly | 109/7305 | 186/18723 | 4.54e-08 | 8.45e-07 | 109 |
| GO:003001016 | Oral cavity | OSCC | establishment of cell polarity | 82/7305 | 143/18723 | 6.56e-06 | 7.24e-05 | 82 |
| GO:006049110 | Oral cavity | OSCC | regulation of cell projection assembly | 100/7305 | 188/18723 | 5.27e-05 | 4.38e-04 | 100 |
| GO:012003216 | Oral cavity | OSCC | regulation of plasma membrane bounded cell projection assembly | 98/7305 | 186/18723 | 1.00e-04 | 7.54e-04 | 98 |
| GO:003514810 | Oral cavity | OSCC | tube formation | 78/7305 | 148/18723 | 4.82e-04 | 2.85e-03 | 78 |
| GO:00070981 | Oral cavity | OSCC | centrosome cycle | 66/7305 | 130/18723 | 4.17e-03 | 1.70e-02 | 66 |
| GO:00310232 | Oral cavity | OSCC | microtubule organizing center organization | 70/7305 | 143/18723 | 9.71e-03 | 3.44e-02 | 70 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05210 | Colorectum | AD | Colorectal cancer | 35/2092 | 86/8465 | 7.54e-04 | 5.49e-03 | 3.50e-03 | 35 |
| hsa04360 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
| hsa052101 | Colorectum | AD | Colorectal cancer | 35/2092 | 86/8465 | 7.54e-04 | 5.49e-03 | 3.50e-03 | 35 |
| hsa043601 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
| hsa052102 | Colorectum | MSS | Colorectal cancer | 36/1875 | 86/8465 | 3.08e-05 | 3.22e-04 | 1.97e-04 | 36 |
| hsa043602 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
| hsa052103 | Colorectum | MSS | Colorectal cancer | 36/1875 | 86/8465 | 3.08e-05 | 3.22e-04 | 1.97e-04 | 36 |
| hsa043603 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DCC | SNV | Missense_Mutation | rs750872111 | c.3257N>T | p.Pro1086Leu | p.P1086L | P43146 | protein_coding | deleterious(0) | possibly_damaging(0.579) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| DCC | SNV | Missense_Mutation | rs767458713 | c.2554G>A | p.Ala852Thr | p.A852T | P43146 | protein_coding | deleterious(0.01) | probably_damaging(0.928) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| DCC | SNV | Missense_Mutation | c.1675C>A | p.Gln559Lys | p.Q559K | P43146 | protein_coding | tolerated(0.55) | benign(0.326) | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DCC | SNV | Missense_Mutation | rs187939463 | c.2647N>A | p.Val883Ile | p.V883I | P43146 | protein_coding | tolerated(0.12) | benign(0.037) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| DCC | SNV | Missense_Mutation | rs750279704 | c.3412N>A | p.Ala1138Thr | p.A1138T | P43146 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-AR-A1AQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| DCC | SNV | Missense_Mutation | rs759439297 | c.632N>A | p.Arg211Gln | p.R211Q | P43146 | protein_coding | tolerated(0.15) | possibly_damaging(0.824) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| DCC | SNV | Missense_Mutation | rs139280277 | c.2887N>A | p.Val963Ile | p.V963I | P43146 | protein_coding | tolerated(1) | benign(0.01) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
| DCC | SNV | Missense_Mutation | rs374199141 | c.4210N>A | p.Glu1404Lys | p.E1404K | P43146 | protein_coding | deleterious(0.01) | possibly_damaging(0.808) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD |
| DCC | SNV | Missense_Mutation | c.287N>G | p.Ser96Cys | p.S96C | P43146 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A1II-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| DCC | SNV | Missense_Mutation | c.704N>C | p.Gly235Ala | p.G235A | P43146 | protein_coding | tolerated(0.18) | benign(0.433) | TCGA-EW-A1J6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |